Drug Profile
Anivamersen-pegnivacogin
Alternative Names: Anivamersen; Pegnivacogin; Pegnivacogin/anivamersen; RB 006; RB 006/RB 007; RB 007; REG-1; REG-2; RevolixysLatest Information Update: 14 Nov 2016
Price :
$50
*
At a glance
- Originator Archemix Corporation
- Developer Tobira Therapeutics
- Class Anticoagulants; Antidotes; Antithrombotics; Nucleotide aptamers; Oligonucleotides
- Mechanism of Action Factor IXa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute coronary syndromes; Venous thrombosis